Brief: Inhibikase Therapeutics Completes 501 Bioequivalence Study Of Ikt-001Pro
17/08/2023 13:34
Aug 17 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES COMPLETION OF THE 501
BIOEQUIVALENCE STUDY OF IKT-001PRO
* INHIBIKASE THERAPEUTICS INC: 600 MG IKT-001PRO
DEMONSTRATED
BIOEQUIVALENCE TO STANDARD-OF-CARE 400 MG DOSE OF IMATINIB
MESYLATE
* INHIBIKASE THERAPEUTICS INC: MINIMAL ADVERSE EVENTS WITH
CONSISTENT DRUG DELIVERY SEEN ACROSS 31 SUBJECTS IN PIVOTAL
TRIAL
* INHIBIKASE THERAPEUTICS INC: TO SUBMIT FDA MEETING REQUEST
TO
DISCUSS REGULATORY APPROVAL PATHWAY
Source text for Eikon: ID:nPn9VC3pNa
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share